Investigation of Potential Action on Behalf of Purchasers of Amarin Corporation plc (Nasadq: AMRN) Securities
Amarin Corporation plc, (“Amarin”) is a pharmaceutical company, which develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Kessler Topaz Meltzer & Check, LLP (“KTMC”) is investigating potential claims on behalf of purchasers of Amarin Corporation plc (Nasadq: AMRN) securities between February 27, 2018 and March 31, 2020.
KTMC’s investigation is related to a recent decision in Amarin’s lawsuit against generic drug manufacturers that filed applications with the FDA to produce generic versions of the Company’s Vascepa, in which the judge ruled that Amarin’s patents were invalid, handing the company a complete loss in its patent infringement lawsuit.
If you purchased shares of Amarin between February 27, 2018 and March 31, 2020, and would like to learn more about our investigation, please fill out our online form or contact us today at 844-887-9500 or info@ktmc.com.